<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Iptacopan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Iptacopan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Iptacopan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="143693" href="/d/html/143693.html" rel="external">see "Iptacopan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58907233"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infections caused by encapsulated bacteria:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Iptacopan, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as <i>Streptococcus pneumoniae</i>, <i>Neisseria meningitidis</i>, and <i>Haemophilus influenzae</i> type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.</p>
<p style="text-indent:-2em;margin-left:2em;">Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of iptacopan, unless the risks of delaying therapy with iptacopan outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients receiving iptacopan are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the risk of serious infections caused by encapsulated bacteria, iptacopan is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58912103"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fabhalta</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58907411"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Complement Factor B Inhibitor;</li>
<li>
                        Complement Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F58921552"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Vaccinate against encapsulated bacteria, including <i>S. pneumoniae, N. meningitidis (serogroups A, C, W, Y, and B), </i>and <i>H. influenzae </i>type B according to current Advisory Committee on Immunization Practices (ACIP) recommendations at least 2 weeks prior to iptacopan initiation; revaccinate according to current ACIP guidelines. If urgent iptacopan treatment is necessary in a patient who is not up to date with <i>S. pneumoniae, N. meningitidis, </i>and <i>H. influenzae </i>type B vaccines according to ACIP recommendations, provide antibacterial prophylaxis and administer the vaccines as soon as possible.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="baae2201-4105-4717-bf6e-c5c875d26f7c">Paroxysmal nocturnal hemoglobinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paroxysmal nocturnal hemoglobinuria: Oral: </b>200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Risitano.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Risitano.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from C5 inhibitors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion from eculizumab:</i> When converting from eculizumab to iptacopan, initiate iptacopan no later than 1 week following the last eculizumab dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion from ravulizumab:</i> When converting from ravulizumab to iptacopan, initiate iptacopan no later than 6 weeks following the last ravulizumab dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> If a dose or doses are missed, administer one iptacopan dose as soon as possible (even if it is soon before the next scheduled dose) and then resume the regular dosing schedule.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58921554"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Kidney function estimated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> without hemodialysis: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> with hemodialysis: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F58921555"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate hepatic impairment (Child-Turcotte-Pugh class A, B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment (Child-Turcotte-Pugh class C): Use is not recommended.</p></div>
<div class="block dot drugH1Div" id="F58921556"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hemolysis (after iptacopan discontinuation): If hemolysis occurs following iptacopan discontinuation, consider restarting iptacopan (if appropriate) or initiating another paroxysmal nocturnal hemoglobinuria (PNH) treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperlipidemia: Initiate cholesterol-lowering medications if indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Evaluate immediately if an infection is suspected. Promptly treat known infections. Consider iptacopan interruption in patients who are undergoing treatment for serious infections. <b></b></p></div>
<div class="block doe drugH1Div" id="F58921553"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58917876"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (8% to 15%), diarrhea (8% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (5% to 11%, including bacterial pneumonia, pyelonephritis, urinary tract infection), viral infection (10% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (19% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (15% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3% to 10%), urticaria (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dyslipidemia (6% to 8%, including hypercholesterolemia, increased LDL cholesterol, increased serum triglycerides)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Infection: Serious infection</p></div>
<div class="block coi drugH1Div" id="F58907232"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity to iptacopan or any component of the formulation; initiation in patients with unresolved serious infection caused by encapsulated bacteria, including <i>S. pneumoniae</i>, <i>N. meningitidis</i>, or <i>H. influenza</i> type B.</p></div>
<div class="block war drugH1Div" id="F58921455"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Iptacopan increases total cholesterol, LDL-cholesterol, and serum triglycerides. Among 2 studies, one-fourth to one-half of iptacopan-treated patients with normal total cholesterol level at baseline developed grade 1 hypercholesterolemia during the treatment period. One patient experienced increased total cholesterol that worsened from grade 1 (at baseline) to grade 2. Among patients in the studies with baseline LDL-cholesterol ≤130 mg/dL, 11% to 17% developed LDL-cholesterol &gt;130 to 160 mg/dL, 3% to 8% developed LDL-cholesterol &gt;160 to 190 mg/dL, and 7% developed LDL-cholesterol &gt;190 mg/dL during the treatment period. Among patients in the studies with normal baseline triglyceride levels approximately one-fourth of patients developed grade 1 elevated triglycerides during the treatment period. Three patients experienced an increase in triglycerides from grade 1 to grade 2. Some patients required cholesterol-lowering medications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Complement inhibitors, including iptacopan, increase the susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including <i>S. pneumoniae, N. meningitidis </i>(caused by any serogroup, including non-groupable strains), and <i>H. influenzae </i>type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. Note that the Advisory Committee on Immunization Practices (ACIP) recommended administration schedule in patients receiving complement inhibitors differs from the administration schedule in the vaccine prescribing information. The optimal prophylactic antibacterial drug regimens and durations and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors (including iptacopan). Consider the benefits and risks of iptacopan treatment (and the benefits and risks of antibacterial drug prophylaxis) in unvaccinated or vaccinated patients versus the known risks for serious infections caused by encapsulated bacteria. Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Inform patients of signs/symptoms and instruct them to seek immediate medical care if infection is suspected. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation in paroxysmal nocturnal hemoglobinuria: Following iptacopan discontinuation, signs/symptoms of hemolysis may occur. Signs/symptoms include elevated lactate dehydrogenase (LDH) levels along with a sudden decrease in hemoglobin or paroxysmal nocturnal hemoglobinuria (PNH) clone size, fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (eg, thrombosis, stroke, and myocardial infarction), dysphagia, or erectile dysfunction. If iptacopan discontinuation is necessary, consider alternative PNH therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program: Due to the risk of serious infections, iptacopan is available only via a restricted REMS program (Fabhalta REMS). REMS information is available at 1-833-99FABHA or at http://www.FABHALTA-REMS.com.</p></div>
<div class="block foc drugH1Div" id="F58912104"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fabhalta: 200 mg</p></div>
<div class="block geq drugH1Div" id="F58912102"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F59040196"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Fabhalta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $904.11</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F58919087"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Iptacopan is available through certified REMS pharmacies. Examples from the manufacturer may be found at https://www.fabhalta-rems.com/#Main.</p></div>
<div class="block adm drugH1Div" id="F58921557"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to food. Swallow whole; do not open, break, or chew capsules.</p></div>
<div class="block meg drugH1Div" id="F59000240"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:-2em;margin-left:2em;">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:0em;margin-left:2em;">Fabhalta: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F218276s000lbl.pdf%23page%3D16&amp;token=QpM1PPzbfrFF3GVIQipk3X3QuKZZ7Vccc0qT6h2vyCeDYKJA3gRa7dqrDus1XxxkrUVqnXGHz6LSYtQBegh%2BNqUgBm5iZu6Jr4EsdNQsQuqi9SnXekPw7tLGaoJL1HQW&amp;TOPIC_ID=143656" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218276s000lbl.pdf#page=16</a></p></div>
<div class="block use drugH1Div" id="F58907231"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Paroxysmal nocturnal hemoglobinuria:</b> Treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults.</p></div>
<div class="block mst drugH1Div" id="F58919085"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fabhalta may be confused with Fabrazyme.</p>
<p style="text-indent:-2em;margin-left:4em;">Iptacopan may be confused with avacopan, pegcetacoplan, zilucoplan.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58932205"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (major), CYP2D6 (minor), UGT1A1, UGT1A3, UGT1A8; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F58932202"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inducers (Moderate): May decrease the serum concentration of Iptacopan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Iptacopan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F58919089"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies conducted in doses 4 to 6 times the maximum recommended human dose (based on AUC).</p></div>
<div class="block brc drugH1Div" id="F58919090"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if iptacopan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer during therapy and for 5 days after the last dose of iptacopan.</p></div>
<div class="block mop drugH1Div" id="F58921559"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Assess immunization status prior to treatment. Monitor serum lipid parameters at baseline and periodically during treatment. Consider monitoring baseline lactate dehydrogenase (LDH). Monitor closely for early signs/symptoms of serious infection and evaluate immediately if an infection is suspected. Following iptacopan discontinuation, closely monitor patients for signs/symptoms of hemolysis for at least 2 weeks after the last dose; signs/symptoms include elevated LDH levels along with a sudden decrease in hemoglobin or paroxysmal nocturnal hemoglobinuria (PNH) clone size, fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (eg, thrombosis, stroke, and myocardial infarction), dysphagia, or erectile dysfunction. Monitor adherence.</p></div>
<div class="block pha drugH1Div" id="F58921459"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Iptacopan is a small-molecule complement factor B inhibitor. Iptacopan binds to factor B of the alternative complement pathway and regulates C3 cleavage, generating downstream effectors, and amplifying the terminal pathway. In paroxysmal nocturnal hemoglobinuria (PNH), intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative complement cascade pathway to control both C3b-mediated EVH and terminal complement-mediated IVH.</p></div>
<div class="block phk drugH1Div" id="F58921460"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Inhibition of alternative pathway biomarkers, in vitro alternative pathway assay and plasma Bb, began ~2 hours after a single initial dose (in healthy volunteers).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~288 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 75% to 93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: ~50% of the dose is attributed to oxidative pathways, including N-dealkylation, O-deethylation, oxidation, and dehydrogenation, predominantly via CYP2C8 (98%), with a minor contribution via CYP2D6 (2%). Iptacopan undergoes phase 2 metabolism through glucuronidation via UGT1A1, UGT1A3, and UGT1A8. Iptacopan accounts for 83% of the drug-related species with 2 minor inactive acyl glucuronide metabolites (8% and 5%) detected in plasma.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~25 hours (at steady state).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (71.5%; 16.8% as parent drug); Urine (24.8%; 17.9% as parent drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 7.96 L/hour (at steady state).</p></div>
<div class="block phksp drugH1Div" id="F58921468"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Unbound iptacopan AUC<sub>inf</sub> was increased by 1.5-, 1.6-, and 3.7-fold in patients with mild (Child-Turcotte-Pugh class A), moderate (Child-Turcotte-Pugh class B), and severe (Child-Turcotte-Pugh class C) hepatic impairment, respectively (compared to subjects with normal hepatic function).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Novartis.1">
<a name="Novartis.1"></a>Fabhalta (iptacopan) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Risitano.1">
<a name="Risitano.1"></a>Risitano AM, Kulasekararaj A, Roeth A, et al. Factor B inhibition with oral iptacopan monotherapy demonstrates sustained long-term efficacy and safety in anti-C5-treated patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia: final 48-week results from the multicenter, phase III APPLY-PNH trial. <i>Blood</i>. 2023;142(suppl 1):571. https://doi.org/10.1182/blood-2023-180780.</div>
</li></ol></div><div id="topicVersionRevision">Topic 143656 Version 13.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
